Sulfobutylether-β-cyclodextrin.

Authors :: Stella VJ
Rajewski RA
Source :: International journal of pharmaceutics [Int J Pharm] 2020 Jun 15; Vol. 583, pp. 119396. Date of Electronic Publication: 2020 May 04.
Publication Year :: 2020
Abstract: This review presents the early history, the motivation, the research and some of the backstories behind the discovery and development of sulfobutylether-β-cyclodextrin as a novel parenterally safe solubilizer and stabilizer. A specific sulfobutylether-β-cyclodextrin with an average degree of 6.5 sulfobutyl-groups variably substituted on the 2-, 3- and 6-hydroxyls of the seven glucopyranose (dextrose) units of β-cyclodextrin, is known by its commercial name, Captisol®. Today it is in 13 FDA approved injectables and numerous clinical candidates. It is also an example of a novel product discovered and initially preclinically developed at an academic institution.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests that could have appeared to influence the work reported in this paper. Professor Stella has consulted for both Gilead and Ligand in the past.<br /> (Copyright © 2020 Elsevier B.V. All rights reserved.)